1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Medimaging Integrated Solution Inc.

Medimaging Integrated Solution Inc.

TTWSE:6796
51.00
TWD
-0.70
(-1.35%)
0.37EPS
153.76P/E
2.29BMarket Cap
Nov 06Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.47
9.65
12.66
14.97
14.1
14.3
14.13
17.3
17.62
Basic EPS, GAAP
1.83
0.15
1.7
2.05
1.97
1.97
0.15
0.2
0.37
Free Cash Flow per Basic Share
-0.26
-1.53
0.45
0.47
1.74
-0.82
-4.54
-1.39
-2.01
Dividend per Share
1.01
1.44
0.14
1.11
1.49
1.59
1.63
0.45
- -
Book Value per Share
11.56
10.28
11.87
14.41
17.34
20.53
19.14
19.49
21.18
Tangible Book Value per Share
11.28
10.05
11.57
14.02
17.02
20.09
18.47
18.77
20.52
Basic Weighted Avg Shares
32
33
32
32
36
38
38
38
39
Sales/Revenue/Turnover
368
315
402
486
502
537
539
661
682
Operating Margin (%)
19.23
1.13
16.93
17.82
11.89
17.25
-0.45
3.15
1.53
Depreciation Expense
16
27
29
33
30
32
55
57
57
Net Income, GAAP
59
5
54
66
70
74
6
8
14
Effective Tax Rate (%)
21.46
5.14
10.14
17.83
19.9
20.36
54.08
47.26
29.79
Profit Margin (%)
15.93
1.52
13.45
13.68
13.95
13.79
1.04
1.17
2.1
Working Capital
270
218
296
377
504
761
580
573
677
LT Debt
39
58
86
70
67
383
395
368
360
Total Equity
380
338
390
486
648
793
742
745
852
Return on Invested Capital (%)
- -
1.22
11.85
12.16
6.93
7.47
-0.14
0.72
-0.38
Return on Capital (%)
- -
1.41
11.45
11.73
10.48
7.98
0.8
1.05
1.82
Return on Common Equity (%)
- -
1.33
14.86
15.17
12.35
10.28
0.73
1.04
1.85

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
305
307
308
LT Borrowings
328
325
323
LT Finance Leases
40
38
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
40
40
Market Capitalization
3,602
2,969
2,289

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,028
1,135
1,117
Cash, Cash Equivalents & STI
547
664
617
Accounts Receivable, Net
175
144
148
Inventories
246
271
298
Total Current Liabilities
455
439
440
Payables & Accruals
- -
- -
- -
ST Debt
305
307
308
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.85%
0.39%
Free Cash Flow
- -
111.3%
-69.22%
Net Income, GAAP
- -
-4.16%
37.7%
Sales/Revenue/Turnover
- -
10.82%
22.72%
Total Cash Common Dividend
- -
138.83%
-72.08%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
97
123
104
215
539
2025
134
155
153
220
661
2026
147
161
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.27
0.06
-0.58
0.93
0.15
2025
0.04
-0.78
0.06
0.88
0.2
2026
-0.32
-0.22
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.63
2025
- -
- -
- -
- -
0.45
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chu Ming Cheng
Full Time Employees
162
Sector
Health technology
Industry
Medical specialties
Address
No. 11, Park Avenue II Hsinchu TP Taiwan 300091
IPO Date
Jun 1, 2022
Website
miis.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medimaging Integrated Solution Inc. Medimaging Integrated Solution Inc. (6796.TW) is a Taiwan-based company engaged in the research, development, manufacture, and marketing of medical imaging and diagnostic equipment. Headquartered in Hsinchu Science Park, Hsinchu, Taiwan, and founded in 2010, the company specializes in portable digital diagnostic solutions, including its flagship Horus Scope brand of hand-held digital scopes; non-mydriatic fundus cameras; digital diagnostic sets for eye, ear, nose, throat, and other five-sense examinations; AI-DR software and devices such as DIB100; telemedicine solutions; and related OEM/ODM services for advanced intelligent medical equipment. It operates globally, distributing products to Europe, the United States, mainland China, and other Asian countries, with certifications including ISO 13485, ISO 9001, FDA, and CE mark to ensure high-quality standards in healthcare and emerging technology applications. Recently, the company partnered with Asahi Intecc to launch a disposable endoscope for animal use and showcased cutting-edge solutions, including participation in Medical Japan 2025 Tokyo and the 2025 Asia Retina Congress, highlighting expansions in veterinary and retina-focused diagnostics.